#Takeda has added a #Covid19 Expansion arm to their phase 1 trial exploring the small molecule TAK-981 in solid tumors and hematologic malignancies. As this #pandemic continues, we will likely see increased numbers of #oncology clinical trials modifying procedures to treat patients with Covid-19. See our study design schema below for trial further details about this trial. #covid #cancer #oncology #clinicaltrials #covid #coronavirus #patients #patientsafety #COVIDー19 #pandemi

While it seems much of our world has come to a halt since the spread of #covid19 , cancer continues to affect the lives of many. Doctors, nurses, and all health-care workers have made #heroic efforts to provide care to victims of the virus and those suffering from long-term illness, all while making every effort to slow the spread of #coronavirus. In the midst of change lies an opportunity to exam current practice in #cancertreatment. Attached is a thought-provoking article e

University of #Penn refuses to stop innovating. After having introduced CAR-T to the fight against #cancer, another Penn team has developed an a related technology which has produced positive results in animal trials. Chimeric Antigen Receptor T cells, or CAR-T, has demonstrated success in treating #bloodcancer, but falls short against solid tumors. The Penn team's new technology, Chimeric Antigen Receptor Macrophages or CAR-M, leverages a similar process of altering the pati

Imalumab is the only drug targeting oxMIF to reach #clinicaltrials, but ultimately was terminated due to poor overall benefit-risk assessment. Now, OncoOne has announced that they have invested in three different modalities targeting oxMIF via distinct mechanisms of action, see link below. Through #aitechnology, Kognitic’s platform will automatically capture the emergence of assets directed at this under-the-radar target and details of their clinical trials, such as other dru

Merck KGaA's MET inhibitor, Tepotinib, received approval in Japan for #NSCLC yesterday, gaining a lead in the tight race against Capmatinib - Novartis' MET inhibitor. The two continue to strive for approval in the United States. #Kognitic's platform highlights the timeline for ongoing trials for both these drugs below. The approval for Tepotinib comes from Merck KGaA's ongoing Vision trial. #Oncology #Analytics #AI #Cancer #LungCancer #Data #Automated #Pharma #MachineLearning

Today is World Cancer Day, a day to reflect upon what strides we have been making toward helping the millions of patients battling cancer and focus on how to continue this momentum. Kognitic would like to celebrate the NIH, institutions, and companies which are sponsoring trials with the endpoints of successful Progression Free Survival and Overall Survival. As shown below, hundreds of trials are currently being run across the most devastating cancers - all with the goal of

#BeiGene presented its upcoming milestones for their #pipeline today at #JPM20, including projected approvals and submissions for #tislelizumab, #zanubrutinib, and #pamiparib. Why wait until the conference for big pharma timelines when #Kognitic's platform has this info available in real-time 365 days a year? #JPMCH20 #Oncology #AI #JPMWeek #Cancer #Automated #JPM2020

#Roche presented its late stage pipeline today at #JPM20, with #tecentriq heading up #oncology with six anticipated indications, including expansions in #HCC, #TNBC, #bladdercancer, #melanoma, #ovariancancer, and #NSCLC. In what other indications and patient segments is tecentriq being tested? #Kognitic's platform makes this information accessible in real-time for clients curious about what is next for this momentum-building asset! See image below for #insights into tecentriq

A next generation CD-19 mAb, tafasitamab is all the buzz at #JPM2020! #Incyte acquired tafasitamab from #Morphosys, who had been developing the drug under the code name MOR00208 (see link below). While the pipeline for targeting CD-19 has been overwhelmingly CAR-T, tafasitamab is leading the way for increased investment in CD-19 antibodies! #Kognitic's platform enhances big pharma portfolio strategies by giving access to real-time data of all target landscapes. View the ima

#JPM2020 is right around the corner! The #Kognitic team is excited to hear from numerous industry leaders what is next for the pharma industry, including keynote speaker Emma Walmsley, CEO at #GlaxoSmithKline! As GSK is currently developing assets across almost 50 cancer indications, she will undoubtedly have great insights to share. See Kognitic's bullseye view below for more detail about GSK's oncology assets! #Oncology #Cancer #AI #Insights #StartupHealth #GSK #Pipeline

The American Cancer Society has released the cancer facts and figures for 2019. With almost 17 million Americans living with a history of cancer last year, we are thrilled to see reports that the overall cancer death rate has dropped approximately 29% since the early 90's, with major declines in prostate cancer (52%), men's lung cancer (51%), and breast cancer (40%)! #Kognitic looks forward to the continued progress against cancer in 2020! #Cancer #Oncology #Progress #Cure #P

Kognitic is excited to be heading to #JPM2020 to discuss the latest in innovative strategy for the pharma industry! Check out our website to see how #Kognitic has been helping to automate trial data anayltics! Kognitic.com #Oncology #ClinicalTrials #StartupHealth #Innovation #Automation

A recent study has found that antibodies which target PD-L1 are more effective than PD-1 inhibitors at blocking PD-1/PD-L1 signaling (see link below). PD-1 has been a prominent target among clinical trials in recent years, with 15 assets currently in Phase 3 for various cancer types (Kognitic, 2019). However, considering this recent finding, PD-L1 may soon replace PD-1 as a leading target for clinical trials. It may also foreshadow increased future revenue for companies with